Mirum's Volixibat Win Rewrites What Investors Thought This Pipeline Could Actually Deliver

Mirum Pharmaceuticals (NASDAQ: MIRM) reports first-quarter 2026 earnings tomorrow, May 6, after market close, with analysts expecting a loss of $0.40 per share—a significant deterioration from the prior year's Q1 loss of $0.30. The central question: can the rare disease specialist sustain the revenue momentum that drove three consecutive earnings beats through mid-2025, or will the sharp Q4 miss signal a fundamental shift in the company's trajectory?

Part 1: Earnings Preview

Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare cholestatic liver diseases, with its lead product Livmarli (maralixibat) approved for treating progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). The company's portfolio addresses significant unmet medical needs in pediatric and adult rare disease populations, making it a focused player in the orphan drug space.

Mirum reports Q1 2026 earnings on May 6 after market close, with the consensus estimate calling for a loss of $0.40 per share. The company most recently reported Q4 2025 earnings of -$0.11 per share on February 25, which badly missed the $0.02 consensus estimate by 650%. Year-over-year, the Q1 estimate represents a 33% deterioration from the $0.30 loss reported in Q1 2025, signaling analysts expect widening losses despite revenue growth expectations of approximately $150.87 million (up 35% from Q1 2025's $111.59 million).

Three key themes define this earnings story:

Commercial Execution and Revenue Trajectory: After posting strong revenue beats in Q2 and Q3 2025 (delivering $127.79M and $133.01M against estimates of $107.91M and $130.11M respectively), investors are watching whether Mirum can sustain this momentum. The Q4 revenue of $148.93 million beat estimates by just 3%, a marked deceleration from prior quarters' outperformance. With Q1 revenue estimated at $150.87 million, the sequential growth rate has slowed dramatically, raising questions about market penetration and competitive dynamics in the rare disease space.

Profitability Path and Operating Leverage: The dramatic Q4 earnings miss—where the company swung from an expected $0.02 profit to an actual $0.11 loss—has refocused attention on Mirum's path to sustained profitability. After briefly turning profitable in Q3 2025 with $0.05 EPS, the company has reverted to losses. Analysts now model widening losses through 2026 (consensus -$1.77 for the full year) before expecting a return to profitability in 2027 ($0.13 EPS). The key question is whether revenue growth can outpace operating expense expansion.

Pipeline Development and Market Expansion: Beyond Livmarli's commercial performance, investors are monitoring progress on label expansions, geographic market penetration, and pipeline development. The company's ability to demonstrate durable demand in its approved indications while advancing new opportunities will be critical to justifying the current valuation and supporting the analyst community's bullish stance.

Ahead of the release, Wall Street maintains a strongly bullish posture with 10 Strong Buy ratings and a mean price target of $129.18, implying 22% upside from current levels. However, the wide range of EPS estimates for Q1 (from -$0.60 to -$0.24) reflects significant uncertainty about near-term profitability, even as analysts remain confident in the long-term revenue story.

Part 2: Historical Earnings Performance

Mirum's recent earnings history reveals a company that consistently surprised to the upside through mid-2025 before stumbling badly in Q4. The pattern is striking: Q1 2025 delivered a 23% positive surprise (-$0.30 actual vs. -$0.39 estimate), Q2 posted a massive 61% beat (-$0.12 vs. -$0.31), and Q3 exceeded expectations by 150% ($0.05 vs. -$0.10), marking the company's first profitable quarter. This three-quarter streak of outperformance suggested Mirum had turned a corner on operational efficiency and revenue scaling.

The Q4 2025 collapse shattered that narrative, with the company reporting a loss of $0.11 per share against expectations of a $0.02 profit—a 650% miss that represented the worst surprise in the company's recent history. This dramatic reversal from profitability to losses, despite revenue continuing to grow and beat estimates, signals either a significant one-time expense event or deteriorating operating margins that analysts failed to anticipate.

The pattern suggests Mirum operates in a volatile earnings environment where quarterly results can swing dramatically based on operating expense timing, R&D investments, or commercial infrastructure buildout. While the company demonstrated an ability to beat lowered expectations consistently through Q3 2025, the Q4 miss has reset investor confidence and likely prompted analysts to adopt more conservative modeling assumptions for 2026.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Mirum typically reports earnings after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price behavior around Mirum earnings shows moderate Day 0 volatility averaging 1.42% as investors position ahead of results, with intraday ranges averaging 4.91%. The real action occurs on Day +1, where the stock has moved an average of 6.82% with intraday ranges stretching to 9.95%—nearly double the Day 0 volatility.

The directional pattern is mixed but leans positive in recent quarters. The February 2026 earnings (Q4 2025 results) triggered a sharp -15.13% Day +1 decline following the massive earnings miss, the largest negative reaction in the dataset. Conversely, August 2025 earnings (Q2 2025 results) sparked a +12.04% Day +1 rally after the company's 61% earnings beat. The May 2025 report (Q1 2025) also generated a strong +9.75% Day +1 gain despite a more modest 23% beat.

This pattern suggests the market rewards meaningful positive surprises with double-digit gains while punishing significant misses with equally severe drawdowns. The average absolute Day +1 move of 6.82% indicates investors should expect meaningful volatility, with the direction heavily dependent on whether Mirum can return to its Q1-Q3 2025 pattern of beating estimates or continues the Q4 2025 trend of disappointing results.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 12.81% through the May 15 expiration, significantly higher than the historical average Day +1 move of 6.82%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction to tomorrow's results, possibly reflecting heightened uncertainty following the dramatic Q4 miss and the wide range of analyst EPS estimates (-$0.60 to -$0.24). The 12.81% expected move is roughly in line with the February 2026 post-earnings decline of 15.13% and the August 2025 rally of 12.04%, indicating the market is pricing in potential for an outsized move in either direction.

Part 3: What Analysts Are Saying

Wall Street maintains a strongly bullish stance on Mirum Pharmaceuticals, with the consensus rating at 4.75 out of 5.0—firmly in Strong Buy territory. The analyst community includes 10 Strong Buy ratings, 1 Moderate Buy, and just 1 Hold, with zero sell ratings. This overwhelmingly positive view reflects confidence in the company's long-term commercial opportunity in rare cholestatic liver diseases, despite near-term profitability challenges.

The mean price target of $129.18 implies 22% upside from the current price of $105.81, with individual targets ranging from a low of $112.00 to a high of $150.00. The relatively tight clustering around the mean (compared to the wide range of EPS estimates) suggests analysts are more aligned on the revenue and long-term value story than on near-term earnings trajectory.

Critically, analyst sentiment has remained unchanged over the past month despite the Q4 earnings miss, indicating the Street views that disappointment as a temporary setback rather than a fundamental deterioration in the investment thesis. The stability in ratings and targets through a significant earnings miss demonstrates conviction that Livmarli's commercial trajectory remains intact and that the path to sustained profitability—while perhaps delayed—is still achievable. Analysts appear to be looking through near-term volatility to focus on 2027, when the consensus models a return to profitability with $0.13 EPS.

Part 4: Technical Picture

Mirum enters earnings with exceptionally strong technical momentum, as the Barchart Technical Opinion has surged to a 100% Buy signal—up dramatically from 72% Buy just one week ago and one month ago. This sharp strengthening reflects powerful bullish momentum building into the release, with the stock breaking out to new highs and attracting increased technical buying interest.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates extremely strong near-term momentum with buyers in full control
• Medium-term (100% Buy): Equally strong intermediate-term reading confirms the uptrend is well-established across multiple timeframes
• Long-term (100% Buy): Maximum long-term bullish signal demonstrates the stock has transitioned into a sustained uptrend with broad-based technical strength

Trend Characteristics: The Strong strength combined with Strongest direction indicates Mirum is in a powerful uptrend with accelerating momentum—an environment that typically amplifies both positive and negative earnings reactions.

The stock is trading at $105.81, positioned above all key moving averages: the 5-day ($99.93), 10-day ($96.39), 20-day ($96.43), 50-day ($93.84), 100-day ($91.50), and 200-day ($80.20). This complete alignment with the stock above every major moving average is a textbook bullish setup, with the rising 200-day average confirming the long-term trend has fully reversed from earlier weakness.

The technical picture is unambiguously supportive heading into earnings, with the stock in a strong uptrend and trading at elevated levels relative to all moving averages. However, this strength also introduces risk: the stock has rallied sharply into the release (up 32% from the 200-day average), creating potential for a "sell the news" reaction if results disappoint or guidance fails to justify the recent run. The 12.81% options-implied move suggests the market is pricing in significant volatility, and with the stock extended above all technical support levels, a negative surprise could trigger a swift retracement toward the 50-day average near $93.84. Conversely, a return to the Q1-Q3 2025 pattern of beating estimates could propel the stock toward the $119.36 upper end of the expected range and potentially challenge the analyst community's mean target of $129.18.